Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.


AbbVie boasts of extending Humira's U.S. monopoly

AbbVie headquarters in Illinois.
AbbVie's headquarters in Illinois. Photo: AbbVie

Bill Chase, chief financial officer of AbbVie, on Wednesday explained the company's long-term strategy for Humira, the top-selling drug in the world, to Wall Street investors at an industry conference:

"You've seen us execute very nicely with our legal strategy and the settlements around the U.S. events to delay the onset of [loss of Humira's exclusivity] into the 2022-2023 time period."

Between the lines: This is a pretty candid moment. Cheaper versions of Humira are hitting European markets next month, and a top AbbVie executive is celebrating two separate deals that would prevent that from happening in the U.S. — where Humira's annual costs are as much as a high-end car — for five years.

More stories loading.